vs

Side-by-side financial comparison of ACACIA RESEARCH CORP (ACTG) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $50.1M, roughly 1.5× ACACIA RESEARCH CORP). On growth, ACACIA RESEARCH CORP posted the faster year-over-year revenue change (2.6% vs -36.9%). Over the past eight quarters, ACACIA RESEARCH CORP's revenue compounded faster (43.6% CAGR vs -34.4%).

Acacia Research Corporation is a publicly traded American company based in New York City. It acquires and operates businesses in industries including the technology, energy, and industrial/manufacturing sectors. Acacia has a strategic relationship with Starboard Value, LP, the company's controlling shareholder. The company has been characterized as a patent troll.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

ACTG vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.5× larger
MED
$75.1M
$50.1M
ACTG
Growing faster (revenue YoY)
ACTG
ACTG
+39.5% gap
ACTG
2.6%
-36.9%
MED
Faster 2-yr revenue CAGR
ACTG
ACTG
Annualised
ACTG
43.6%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACTG
ACTG
MED
MED
Revenue
$50.1M
$75.1M
Net Profit
$3.4M
Gross Margin
12.8%
69.4%
Operating Margin
-26.1%
-10.4%
Net Margin
6.8%
Revenue YoY
2.6%
-36.9%
Net Profit YoY
125.5%
EPS (diluted)
$0.03
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACTG
ACTG
MED
MED
Q4 25
$50.1M
$75.1M
Q3 25
$59.4M
$89.4M
Q2 25
$51.2M
$105.6M
Q1 25
$124.4M
$115.7M
Q4 24
$48.8M
$119.0M
Q3 24
$23.3M
$140.2M
Q2 24
$25.8M
$168.6M
Q1 24
$24.3M
$174.7M
Net Profit
ACTG
ACTG
MED
MED
Q4 25
$3.4M
Q3 25
$-2.7M
$-2.3M
Q2 25
$-3.3M
$2.5M
Q1 25
$24.3M
$-772.0K
Q4 24
$-13.4M
Q3 24
$-14.0M
$1.1M
Q2 24
$-8.4M
$-8.2M
Q1 24
$-186.0K
$8.3M
Gross Margin
ACTG
ACTG
MED
MED
Q4 25
12.8%
69.4%
Q3 25
21.2%
69.5%
Q2 25
12.8%
72.6%
Q1 25
47.4%
72.8%
Q4 24
17.6%
74.1%
Q3 24
10.1%
75.4%
Q2 24
26.2%
73.2%
Q1 24
49.2%
72.8%
Operating Margin
ACTG
ACTG
MED
MED
Q4 25
-26.1%
-10.4%
Q3 25
-10.8%
-4.6%
Q2 25
-24.2%
-1.0%
Q1 25
30.8%
-1.1%
Q4 24
-32.4%
0.6%
Q3 24
-44.1%
1.5%
Q2 24
-18.4%
-4.7%
Q1 24
-8.6%
4.5%
Net Margin
ACTG
ACTG
MED
MED
Q4 25
6.8%
Q3 25
-4.6%
-2.5%
Q2 25
-6.4%
2.3%
Q1 25
19.5%
-0.7%
Q4 24
-27.5%
Q3 24
-60.0%
0.8%
Q2 24
-32.7%
-4.8%
Q1 24
-0.8%
4.8%
EPS (diluted)
ACTG
ACTG
MED
MED
Q4 25
$0.03
$-1.64
Q3 25
$-0.03
$-0.21
Q2 25
$-0.03
$0.22
Q1 25
$0.25
$-0.07
Q4 24
$-0.14
$0.08
Q3 24
$-0.14
$0.10
Q2 24
$-0.08
$-0.75
Q1 24
$0.00
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACTG
ACTG
MED
MED
Cash + ST InvestmentsLiquidity on hand
$306.7M
$167.3M
Total DebtLower is stronger
$91.9M
Stockholders' EquityBook value
$543.5M
$198.9M
Total Assets
$771.0M
$248.0M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACTG
ACTG
MED
MED
Q4 25
$306.7M
$167.3M
Q3 25
$301.8M
$173.5M
Q2 25
$316.7M
$162.7M
Q1 25
$272.0M
$164.6M
Q4 24
$273.9M
$162.3M
Q3 24
$410.9M
$170.0M
Q2 24
$441.9M
$163.5M
Q1 24
$498.4M
$156.4M
Total Debt
ACTG
ACTG
MED
MED
Q4 25
$91.9M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACTG
ACTG
MED
MED
Q4 25
$543.5M
$198.9M
Q3 25
$537.6M
$214.7M
Q2 25
$538.6M
$216.0M
Q1 25
$540.2M
$211.0M
Q4 24
$514.8M
$210.1M
Q3 24
$540.2M
$207.3M
Q2 24
$560.7M
$205.3M
Q1 24
$568.3M
$211.0M
Total Assets
ACTG
ACTG
MED
MED
Q4 25
$771.0M
$248.0M
Q3 25
$768.9M
$268.2M
Q2 25
$775.5M
$269.3M
Q1 25
$801.6M
$280.0M
Q4 24
$756.4M
$284.2M
Q3 24
$707.6M
$291.2M
Q2 24
$753.6M
$293.5M
Q1 24
$631.7M
$302.8M
Debt / Equity
ACTG
ACTG
MED
MED
Q4 25
0.17×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACTG
ACTG
MED
MED
Operating Cash FlowLast quarter
$75.2M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
22.01×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACTG
ACTG
MED
MED
Q4 25
$75.2M
$-5.3M
Q3 25
$9.5M
$12.1M
Q2 25
$50.1M
$-3.4M
Q1 25
$2.4M
$3.4M
Q4 24
$50.1M
$-4.9M
Q3 24
$-593.0K
$9.1M
Q2 24
$16.1M
$13.1M
Q1 24
$54.8M
$7.3M
Free Cash Flow
ACTG
ACTG
MED
MED
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$335.0K
$1.9M
Q4 24
$-98.5M
$-7.2M
Q3 24
$-2.8M
$7.7M
Q2 24
$-126.7M
$11.1M
Q1 24
$54.6M
$5.4M
FCF Margin
ACTG
ACTG
MED
MED
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
0.3%
1.6%
Q4 24
-201.8%
-6.1%
Q3 24
-12.1%
5.5%
Q2 24
-490.5%
6.6%
Q1 24
224.4%
3.1%
Capex Intensity
ACTG
ACTG
MED
MED
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.7%
1.3%
Q4 24
304.4%
1.9%
Q3 24
9.6%
1.0%
Q2 24
553.0%
1.1%
Q1 24
1.1%
1.1%
Cash Conversion
ACTG
ACTG
MED
MED
Q4 25
22.01×
Q3 25
Q2 25
-1.36×
Q1 25
0.10×
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACTG
ACTG

Energy Operations$16.0M32%
Transportation Safety$10.4M21%
Office Storage And Display Solutions$8.4M17%
Printers Consumables And Parts$6.5M13%
Natural Gas Reserves$5.1M10%
Natural Gas Liquids Reserves$3.3M7%

MED
MED

Segment breakdown not available.

Related Comparisons